Plus Therapeutics Stock Soars 36% Amid $1.6M CPRIT Funding and Promising Clinical Trial Results

Company Overview

PLUS THERAPEUTICS INC (Nasdaq: PSTV) is a Houston‐based clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for adults and children with rare and difficult-to-treat cancers. The company combines Rhenium radioisotopes with proprietary nanoliposome and alginate microsphere delivery systems to localize therapeutic radiation doses directly at tumor sites, aiming to preserve surrounding healthy tissue.

Corporate Structure and Operations

Originally founded as Cytori Therapeutics and rebranded in 2019, Plus Therapeutics employs between 11 and 50 staff members across its corporate headquarters and research facilities. The company’s pipeline activities include:

• REYOBIQ™ (rhenium Re186 obisbemeda) for central nervous system (CNS) cancers such as recurrent glioblastoma and leptomeningeal metastases.
• A next-generation radioembolization therapy using Rhenium-188 microspheres for primary and metastatic liver cancers.
  In addition, subsidiary CNSide Diagnostics supports biomarker development and clinical trial recruitment.

Radiotherapeutics by Marcel Strauß

Developments and News

• 2025-07-18 (Form 8-K Filing): Plus Therapeutics reported a change in its certifying accountant.
• 2025-07-21 (Annual Report to Security Holders): The company filed its Annual Report (ARS), which includes details regarding fiscal 2024 R&D investments, cash position, and risk factors.
• 2025-07 (CPRIT Funding): The company received an advance payment of $1.6 million from the Cancer Prevention and Research Institute of Texas, as part of a $17.6 million award to support the development of radiotherapeutics for leptomeningeal cancer.
• Clinical Trial Progress: Enrollment continues in the multi-center ReSPECT trials (NCT01906385). Phase 1/2 results for REYOBIQ in recurrent glioma patients who received absorbed doses above 100 Gy indicated a median overall survival of 17 months.
• Recruitment Activity: As of July 2025, the company has posted job openings for Medical Science Liaison positions to support its oncology and diagnostics functions.

Financial and Strategic Analysis

As of 2025-07-24, PSTV shares traded at $0.6692, reflecting a price increase of 36.57% on high trading volume of 29,748,335 shares. This movement coincides with the receipt of funding from CPRIT and ongoing clinical trial developments. The forthcoming 2025 ARS is expected to provide details on the company’s cash runway, R&D expenditures, and operational costs. Plus Therapeutics aims to advance REYOBIQ toward FDA approval while expanding its radiotherapeutic platform into additional solid organ indications utilizing Rhenium-188. The company holds key patents on BMEDA-mediated nanoliposome encapsulation.

Market Position and Industry Context

The global radiopharmaceutical market includes established companies in diagnostic imaging and emerging entities specializing in therapeutic isotopes. Plus Therapeutics focuses on precision oncology, addressing CNS and hepatic tumors through localized radiation delivery. Its emphasis on rare and difficult-to-treat indications differentiates it from broader oncology developers. Support from grantors like CPRIT and a diversified pipeline of multiple isotopes position PSTV to address the demand for targeted radiotherapy solutions.

tl;dr

On 2025-07-24, PLUS THERAPEUTICS’ stock was priced at $0.6692, reflecting a 36.57% increase following a $1.6 million advance from CPRIT under a $17.6 million grant. The company continues enrolling patients in ReSPECT trials of REYOBIQ for glioblastoma and leptomeningeal metastases, based on Phase 1/2 data indicating a median survival at doses over 100 Gy. A Form 8-K on 2025-07-18 reported a change in auditor, and the 2025 Annual Report will detail cash position and R&D expenditures.